Schrödinger logo

Schrödinger

North America, New York, United States, New York

Description

Schrödinger is a healthcare-based software company that develops molecular design software for biotech and materials research.

Investor Profile

Schrödinger has made 9 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (33%)
  • Series B (22%)
  • Series C (22%)
  • Series A (11%)
  • Series Unknown (11%)

Country Focus

  • United States (89%)
  • Canada (11%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Life Science
  • Pharmaceutical
  • Product Research
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Schrödinger frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 3
Omega Funds
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 3
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
IO
North America, New York, United States, New York
Co-Investments: 2
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 3
ShangPharma
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 2

Which angels does Schrödinger often collaborate with?

BG
North America, Washington, United States, Seattle
Shared Deals: 1
TA
North America, Massachusetts, United States, Cambridge
Shared Deals: 3

What are some of recent deals done by Schrödinger?

Ajax Therapeutics

Cambridge, Massachusetts, United States

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

BiotechnologyLife ScienceMedical
Series CMay 13, 2024
Amount Raised: $95,000,000
Structure Therapeutics

South San Francisco, California, United States

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

BiotechnologyHealth CareMedicalPharmaceuticalProduct Research
Series BOct 20, 2021
Amount Raised: $100,000,000
Ajax Therapeutics

Cambridge, Massachusetts, United States

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

BiotechnologyLife ScienceMedical
Series UnknownJun 1, 2021
Amount Raised: $40,000,000
Bright Angel Therapeutics

Toronto, Ontario, Canada

Bright Angel Therapeutics is developing new drugs that can prevent or revert the emergence of antifungal resistance.

Biotechnology
SeedDec 3, 2019
Morphic Therapeutic

Waltham, Massachusetts, United States

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

BiotechnologyHealth CareMedicalTherapeutics
Series BSep 25, 2018
Amount Raised: $80,000,000
Nimbus Therapeutics

Boston, Massachusetts, United States

Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.

BiotechnologyHealth CareTherapeutics
Series CJun 5, 2018
Amount Raised: $65,000,000
Morphic Therapeutic

Waltham, Massachusetts, United States

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

BiotechnologyHealth CareMedicalTherapeutics
Series AJun 30, 2016
Amount Raised: $51,500,000
Morphic Therapeutic

Waltham, Massachusetts, United States

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

BiotechnologyHealth CareMedicalTherapeutics
SeedJan 1, 2016
Amount Raised: $3,000,000
Nimbus Therapeutics

Boston, Massachusetts, United States

Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.

BiotechnologyHealth CareTherapeutics
SeedApr 29, 2010
Amount Raised: $3,500,000